Barw Medical Journal
Submit your article

Review Articles Barw Medical Journal. 2024

Presentation and Management of Porocarcinoma: A Systematic Review with Meta-Analysis of More Than One Thousand Patients

, , , , , , , , , , , ,

Aland S. Abdullah

  • 1College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

7 articles in this journal

Suhaib H. Kakamad

  • 2Department of Immunology and Hematology, College of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran

21 articles in this journal

Fakher Abdullah

  • 3Kscien Organization for Scientific Research (Middle east Office), Azadi Mall, Hamid Street, Sulaymaniyah, Iraq

20 articles in this journal

Yousif M. Mahmood

  • 4Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

22 articles in this journal

Gona M. Fatah

  • 5Department of Biology, College of Education, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq

3 articles in this journal

Imad J. Habibullah

  • 6Bakhshin Medical Community Halabja, Halabja, Sulaymaniyah, Kurdistan, Iraq

7 articles in this journal

Ronak S. Ahmed

  • 7Department of Dermatology, Teaching Center for Treating Skin Diseases, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq

6 articles in this journal

Rebaz H. Ali

  • 8Hiwa Cancer Hospital Centre, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq

Ari M. Abdullah

  • 9Department of Pathology, Sulaimani Surgical Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq

17 articles in this journal

Hiwa O. Abdullah

  • 4Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

28 articles in this journal

Berun A. Abdalla

  • 10Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

61 articles in this journal

Rawezh Q. Salih

  • 11Department of Biology, College of Science, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq

19 articles in this journal

Abdulwahid M. Salih

  • 1College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq

44 articles in this journal

  • 1College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
  • 2Department of Immunology and Hematology, College of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran
  • 3Kscien Organization for Scientific Research (Middle east Office), Azadi Mall, Hamid Street, Sulaymaniyah, Iraq
  • 4Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
  • 5Department of Biology, College of Education, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq
  • 6Bakhshin Medical Community Halabja, Halabja, Sulaymaniyah, Kurdistan, Iraq
  • 7Department of Dermatology, Teaching Center for Treating Skin Diseases, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq
  • 8Hiwa Cancer Hospital Centre, Sulaimani Directorate of Health, Sulaymaniyah, Kurdistan, Iraq
  • 9Department of Pathology, Sulaimani Surgical Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq
  • 10Department of Biology, College of Education, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
  • 11Department of Biology, College of Science, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq
Submitted
25 Jan 2024
Accepted
22 Mar 2024
Published
7 Mar 2024
Reads
2,733
Downloads
599
Citations
2 Citations are Crossref’s count on 8 November 2026.

doi:10.58742/7xjek960 Open access CC BY 4.0 licence (opens in a new tab)

Download PDF XML

Abstract

IntroductionPorocarcinoma is an aggressive cutaneous carcinoma arising from the intraepidermal component of the sweat glands. Given its uncommon nature, only a limited number of studies have addressed this issue. This study summarizes the different presentations and management of the disease.

MethodsThe eligible databases were searched to identify English-language studies published up to January 16th, 2024. The inclusion criteria comprised studies that focused on the presentation and management of eccrine porocarcinoma, with a clear statement of the outcomes of the chosen management. The data collected from the studies included the first author's name, country of study, type of study design, patient demography, the clinical presentation of the tumor and its location, histopathological findings, metastasis status, treatment strategy, and the subsequent prognosis.

ResultsThe initial search yielded 817 papers, with only 22 meeting the inclusion criteria. The studies comprised 1004 patients with a mean age of 78.7 years. In total, 527 (52.5%) of them were male and 461(45.9%) were female. The most commonly affected regions were the head and neck followed by the lower extremities. The most frequent treatment option was surgical excision in 876 (87.3%) patients. Distant metastasis accounted for about 2%, while lymph node involvement, occurred in 36 cases (3.6%). A good prognosis was reported in 57.3% of the cases. Both the age and tumor size had a significant effect on prognosis (p <0.05).

Conclusion
The lesion can develop anywhere on the body, with a survival rate exceeding 50%. Wide-based surgical excision remains the predominant treatment option.

Keywords Porocarcinoma Cutaneous carcinoma Skin cancer Aggressive cancer Infiltrating tumor All subjects

Sections3

The full text is in the PDF of record

This article was published as a typeset PDF and XML. The abstract above is the version of record’s own summary; the complete text, its figures, its tables and its reference list are in the files below.

Read the PDF XML
Citable now
Barw Medical Journal. 2024
Where it sits

References35

  1. Stuart A. Miyamoto K, Yanagi T, Maeda T, Ujiie H. Diagnosis and management of porocarcinoma. Cancers. 2022;14(21):5232. doi:10.3390/cancers14215232.

    10.3390/cancers14215232CrossrefPubMedScopusGoogle Scholar

  2. De Giorgi V, Silvestri F, Savarese I, Venturi F, Scarfì F, Trane L, et al. Porocarcinoma: an epidemiological, clinical, and dermoscopic 20‐year study.2022; 61(9): 1098-1105. doi:10.1111/ijd.16129.

    10.1111/ijd.16129CrossrefPubMedScopusGoogle Scholar

  3. Lloyd MS, El-Muttardi N, Robson A. Eccrine porocarcinoma: a case report and review of the literature. Canadian Journal of Plastic Surgery. 2003;11(3):153-6. doi:10.1177/229255030301100304.

    10.1177/229255030301100304CrossrefPubMedScopusGoogle Scholar

  4. Biondi E, Ranieri G, Nicolò A, Gasparini G. A unique case of eccrine porocarcinoma with pulmonary lymphangitis and pericardial involvement: biological characterization and clinical aggressiveness. Oncology. 2000;59(3):190-5. doi:10.1159/000012160.

    10.1159/000012160CrossrefPubMedScopusGoogle Scholar

  5. Park S, Kim JH. Concurrent presentation of porocarcinoma and basal cell carcinoma arising on a capillary malformation: a case report. Archives of Craniofacial Surgery. 2023;24(5):236. doi:10.7181%2Facfs.2023.00388.

    CrossrefPubMedGoogle Scholar

  6. Le HM, Faugeras L, De Moor V, Fervaille C, Vander Borght T, Collette F, et al. Eccrine porocarcinoma: a challenging diagnostic and therapeutic tumoral entity. Case reports in oncology. 2021;14(2):700-5. doi:10.1159/000514984.

    10.1159/000514984CrossrefPubMedScopusGoogle Scholar

  7. Sawaya JL, Khachemoune A. Poroma: a review of eccrine, apocrine, and malignant forms. International Journal of Dermatology. 2014;53(9):1053-61. doi:10.1111/ijd.12448.

    10.1111/ijd.12448CrossrefPubMedScopusGoogle Scholar

  8. Shiohara J, Koga H, Uhara H, Takata M, Saida T. Eccrine porocarcinoma: clinical and pathological studies of 12 cases. The Journal of dermatology. 2007;34(8):516-22. doi:10.1111/j.1346-8138.2007. 00324.x

    10.1111/j.1346-8138.2007CrossrefPubMedScopusGoogle Scholar

  9. Luz MD, Ogata DC, Montenegro MF, Biasi LJ, Ribeiro LC. Eccrine porocarcinoma (malignant eccrine poroma): a series of eight challenging cases. Clinics. 2010; 65:739-42. doi:10.1590/S1807-59322010000700014.

    10.1590/S1807-59322010000700014CrossrefPubMedScopusGoogle Scholar

  10. Orella JA, Peñalba AV, San Juan CC, Nadal RV, Morrondo JC, Alvarez TT. Eccrine porocarcinoma: report of nine cases. Dermatologic surgery. 1997;23(10):925-8. doi:10.1111/j.1524-4725. 1997.tb00751.x

    10.1111/j.1524-4725CrossrefPubMedScopusGoogle Scholar

  11. Mahomed F, Blok J, Grayson W. The squamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases. Journal of clinical pathology. 2008;61(3):361-5. doi:10.1136/jcp.2007.049213.

    10.1136/jcp.2007.049213CrossrefPubMedScopusGoogle Scholar

  12. Kurashige Y, Minemura T, Nagatani T. Eccrine porocarcinoma: clinical and pathological report of eight cases. Case reports in dermatology. 2013;5(3):259-66. doi:10.1159/000355606.

    10.1159/000355606CrossrefPubMedScopusGoogle Scholar

  13. Gu LH, Ichiki Y, Kitajima Y. Aberrant expression of p16 and RB protein in eccrine porocarcinoma. Journal of cutaneous pathology. 2002;29(8):473-9. doi:10.1034/j.1600-0560.2002. 290805.x

    10.1034/j.1600-0560.2002CrossrefPubMedScopusGoogle Scholar

  14. Xu YG, Aylward J, Longley BJ, Hinshaw MA, Snow SN. Eccrine porocarcinoma treated by Mohs micrographic surgery: over 6-year follow-up of 12 cases and literature review. Dermatologic Surgery. 2015;41(6):685-92. doi:10.1097/DSS.0000000000000382.

    10.1097/DSS.0000000000000382CrossrefPubMedScopusGoogle Scholar

  15. Zahn J, Chan MP, Wang G, Patel RM, Andea AA, Bresler SC, et al. Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma. Journal of Cutaneous Pathology. 2019;46(9):659-64. doi:10.1111/cup.13480

    10.1111/cup.13480CrossrefPubMedScopusGoogle Scholar

  16. Yamamoto O, Haratake J, Yokoyama S, Imayama S, Asahi M. A histopathological and ultrastructural study of eccrine porocarcinoma with special reference to its subtypes. Virchows Archiv A. 1992;420: 395-401. doi:10.1007/BF01600510.

    10.1007/BF01600510CrossrefPubMedScopusGoogle Scholar

  17. Meriläinen AS, Von WILLEBRAND-BÄCKMAN M, Sihto H, Koljonen V. Eccrine Porocarcinoma: Clinical and Histopathological Study of 14 Patients with Special Emphasis on Sentinel Lymph Node Biopsy. Acta Dermato-Venereologica. 2023;103: 11649. doi:10.2340%2Factadv.v103.11649

    CrossrefPubMedGoogle Scholar

  18. Kazakov DV, Kutzner H, Spagnolo DV, Kempf W, Zelger B, Mukensnabl P, et al. Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). The American journal of dermatopathology. 2008;30(1): 21-6. doi:10.1097/DAD.0b013e31815f2ae3.

    10.1097/DAD.0b013e31815f2ae3CrossrefPubMedScopusGoogle Scholar

  19. Gómez-Zubiaur A, Medina-Montalvo S, Vélez-Velázquez MD, Polo-Rodríguez I. Eccrine porocarcinoma: patient characteristics, clinical and histopathologic features, and treatment in 7 cases. Actas Dermo-Sifiliográficas (English Edition). 2017 ;108(4):e27-32. doi:10.1016/j.ad.2016.04.024

    10.1016/j.ad.2016.04.024CrossrefPubMedScopusGoogle Scholar

  20. Villena JP, Ke BN, Ciriaco-Tan CP. Malignant Mystique: Porocarcinoma in Three Adult Filipinos. Acta Medica Philippina. 2020;54(3):327-31. doi:10.47895/amp.v54i3.1681

    10.47895/amp.v54i3.1681CrossrefPubMedScopusGoogle Scholar

  21. Shope C, Andrews L, Forcucci J. Comparing Porocarcinoma Outcomes Following Resection by Surgical Management Technique. SKIN The Journal of Cutaneous Medicine. 2023;7(6): 1161-4. doi:10.25251/skin.7.6.13

    10.25251/skin.7.6.13CrossrefPubMedScopusGoogle Scholar

  22. Yazar SK, Serin M. Results of surgical treatment of patients with malignant eccrine poroma. Şişli Etfal Hastanesi Tip Bülteni. 2019;53(1): 33-6. doi:10.14744/SEMB.2018.10170

    10.14744/SEMB.2018.10170CrossrefPubMedScopusGoogle Scholar

  23. Goto K, Takai T, Fukumoto T, Anan T, Kimura T, Ansai SI, et al. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma. Journal of Cutaneous Pathology. 2016;43(3): 219-26. doi:10.1111/cup.12632

    10.1111/cup.12632CrossrefPubMedScopusGoogle Scholar

  24. Kervarrec T, Frouin E, Collin C, Tallet A, Tallegas M, Pissaloux D, et al. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1‐deficient skin carcinoma. Histopathology. 2023;82(6):885-98. doi:10.1111/his.14874

    10.1111/his.14874CrossrefPubMedScopusGoogle Scholar

  25. Puttonen M, Isola J, Ylinen O, Böhling T, Koljonen V, Sihto H. UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma. Scientific Reports. 2022;12(1):5529. doi:10.1038/s41598-022-09490-5

    10.1038/s41598-022-09490-5CrossrefPubMedScopusGoogle Scholar

  26. Joshy J, van Bodegraven B, Mistry K, Craig P, Rajan N, Vernon S, et al. Epidemiology of porocarcinoma in England 2013-18: a population-based registry study. Clinical and Experimental Dermatology. 2023;48(7):770-77. doi:10.1093/ced/llad122

    10.1093/ced/llad122CrossrefPubMedScopusGoogle Scholar

  27. Riera‐Leal L, Guevara‐Gutiérrez E, Barrientos‐García JG, Madrigal‐Kasem R, Briseño‐Rodríguez G, Tlacuilo‐Parra A. Eccrine porocarcinoma: epidemiologic and histopathologic characteristics. International Journal of Dermatology. 2015;54(5): 580-6. doi:10.1111/ijd.12714

    10.1111/ijd.12714CrossrefPubMedScopusGoogle Scholar

  28. Belin E, Ezzedine K, Stanislas S, Lalanne N, Beylot‐Barry M, Taieb A, Vergier B, Jouary T. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. British Journal of Dermatology. 2011;165(5): 985-9. doi:10.1111/j.1365-2133.2011. 10486.x

    10.1111/j.1365-2133.2011CrossrefPubMedScopusGoogle Scholar

  29. Kim HJ, Kim A, Moon KC, Seo SH, Kim IH, Kim A, Baek YS. Eccrine porocarcinoma: a multicenter retrospective study with review of the literatures reported in Korea. Annals of Dermatology. 2020;32(3): 223. doi:10.5021/ad.2020.32.3.223

    10.5021/ad.2020.32.3.223CrossrefPubMedScopusGoogle Scholar

  30. Muhialdeen AS, Ahmed JO, Baba HO, Abdullah IY, Hassan HA, Najar KA, et al: Kscien's List; A New Strategy to Discourage Predatory Journals and Publishers (Second Version). Barw Medical Journal. 2023; 1 (1): 24 26. doi:10.58742/Barw Medical Journal. v1i1.14

    10.58742/BarwCrossrefPubMedScopusGoogle Scholar

  31. Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Annals of medicine and surgery. 2017;20: 74-9. doi:10.1016/j.amsu.2017.06.027

    10.1016/j.amsu.2017.06.027CrossrefPubMedScopusGoogle Scholar

  32. Mahmood ZH, Mohemed FM, Fatih BN, Qadir AA, Abdalla SH. Cancer publications in one year (2022); a cross-sectional study. Barw Medical Journal. 2023;1(2):18-26. doi:10.58742/bmj.v1i2.30

    10.58742/bmj.v1i2.30CrossrefPubMedScopusGoogle Scholar

  33. Fujimura T, Hashimoto A, Furudate S, Kambayashi Y, Haga T, Aiba S. Successful treatment of eccrine porocarcinoma metastasized to a cervical lymph node with CyberKnife radiosurgery. Case Reports in Dermatology. 2014;6(2): 159-63. doi:10.1159/000365348

    10.1159/000365348CrossrefPubMedScopusGoogle Scholar

  34. Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. The American journal of surgical pathology. 2001;25(6): 710-20. doi:10.1097/00000478-200106000-00002.

    10.1097/00000478-200106000-00002CrossrefPubMedScopusGoogle Scholar

  35. Asghar AH, Mahmood H, Faheem M, Rizvi S, Khan KA, Irfan J. Porocarcinoma: a rare sweat gland malignancy. J Coll Physicians Surg Pak. 2009;19(6): 389-90. doi: N/A

    CrossrefPubMedGoogle Scholar

Copyright © 2024 The Author(s)

  • Surgical Outcomes Following First Rib Resection for Neurogenic Thoracic Outlet Syndrome: A Systematic Review of 1,334 Operated Sides

    Fahmi H. Kakamad, Saywan K. Asaad, Sanaa O. Karim, Abdullah K. Ghafour, Hiwa S. Namiq, Hawkar A. Nasralla, Lawand A. Sharif, Choman S. Omer and 5 more

    Introduction Neurogenic thoracic outlet syndrome (NTOS) is the most common subtype of thoracic outlet syndrome and results from compression of the brachial plexus within the thoracic outlet. First rib resection (FRR) is considered the cornerstone of surgical management in patients with refractory symptoms, although…

    2026 1,991 reads 0 citations

    doi:10.58742/bmj.v4i1.234

    Full text PDF XML

  • Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals

    Fahmi H. Kakamad, Shvan H. Mohammed, Berun A. Abdalla, Dahat A. Hussein, Zuhair D. Hammood, Suhaib H. Kakamad, Diyar A. Omar, Kayhan A. Najar and 6 more

    The rapid growth of open access publishing (OAP) has significantly improved the accessibility and dissemination of scientific knowledge. However, this expansion has also contributed to the emergence of non-recommended journals (NRJs) and non-recommended publishers (NRPs) that exploit researchers by offering rapid…

    2026 2,535 reads 17 citations

    doi:10.58742/bmj.v4i1.227

    Full text PDF XML

  • Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials

    Rebaz M. Ali, Karukh K. Mohammed, Sasan M. Ahmed, Kayhan A. Najar, Mohammed Q. Mustafa, Zanyar K. Hama, Shadan A. Hamad, Maria A. Rasool and 4 more

    Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCLC) after progression on platinum-based therapy. This meta-analysis evaluated the efficacy and safety of tarlatamab as monotherapy and in combination…

    2025 5,636 reads 1 citation

    doi:10.58742/bmj.v4i1.216

    Full text PDF XML

PDF